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INTRODUCTION
Chickenpox is an acute and highly contagious infection caused by 
the varicella-zoster virus (VZV).1 Varicella-zoster virus (VZV) is an 
exceptionally infectious virus. It presents as chickenpox when primary 
infection occurs and as herpes zoster (HZ) when it reactivates. The 
U.S. Centers for Disease Control and Prevention (CDC) recommend 
administering the VZV vaccine at baseline to every non-immune 
healthcare worker. In the event of exposure to VZV, CDC recommends 
immediate vaccination to prevent the dissemination of infection and 
furlough from the workplace for 10 - 21 days.2 
Since 2006, the Advisory Committee on Immunization Practices 
(ACIP) recommends varicella vaccination (Varivax®) as a routine 
two-dose vaccine for children older than 12 months.3 Zoster vaccine 
(Zostavax®) was approved by the U.S. Food and Drug Administration 
(FDA) to prevent shingles among adults 60 years and older, with or 
without the prior history of reported infection.4 The FDA has expanded 
the vaccination administration for those who are 50 years and older. 
However, there were no studies present on the safety of this vaccine 
in those who had a history of zoster in the past. The implementation 
of universal immunization in children against varicella has led to a 
decrease in varicella incidence by 85%; however, about 30% of the 
adult population can still develop herpes zoster.3 
In the healthcare settings, susceptible (non-immune) persons of all 
ages are at higher risk for severe varicella disease. Generalized rash 
from varicella vaccine is uncommon and described in 1 - 5% of the vac-
cinated persons, usually characterized by 5 - 50 lesions; however, it is 
enormously contagious. Herpes zoster involvement of the trigeminal 
nerve of the ophthalmic division can lead to distressing consequences. 
It is thought to be a result of cell-mediated immunity against the viral 
antigens in the eye.5 There are two types of vaccines available in the 
U.S. Varivax®, a live attenuated varicella vaccine, has been reported to 
cause many ocular complications.6 On the other hand, Zostavax® has 
been linked to fewer ocular complications. Despite that fact, a case of 
interstitial keratitis in a 50-year-old woman, 35 days after receiving 
the Zostavax® vaccine, has been reported.7 She also had manifested 
multiple recurrences of her ocular disease expositions.
In this case report, a health worker case was described who devel-
oped generalized body rash and bilateral retinal necrosis 7 weeks and 
14 weeks after the post-exposure vaccine, respectively.
CASE REPORT
A 42-year-old, male health worker was exposed to another health 
worker who had developed a typical chickenpox rash in a tertiary care 
hospital before being diagnosed. The patient was found non-immune, 
furloughed for days 10 - 21, and vaccinated with varicella vaccine three 
weeks after exposure. The patient's general past medical history was 
insignificant, with no varicella disease as a child. He also denied any 
immunodeficiency or other vaccine contraindications. The patient also 
had an unremarkable ophthalmological history in the past. However, at 
seven weeks after exposure (four weeks after vaccination), the patient 
presented at occupational health service (OHS) with generalized 
vesicular rash, characteristic for chickenpox. The health care worker 
also reported malaise, arthralgia, and body aches. The patient denied 
any fever. On physical examination, he had numerous widespread ves-
icles with erythematous bases all over the body. Molecular testing of a 
specimen from one of the rash lesions was positive for varicella-zoster 
virus (VZV). Subsequent analysis of markers that discriminate against 
the vaccine strain (Oka virus) from the wild type strain (open reading 
frame ORF 38 and ORF54) indicated that the patient VZV strain was 
consistent with the Oka virus vaccine and not wild type. Furthermore, 
vaccine strain-specific markers (ORF62) indicated that the patient 
VZV strain was consistent with the Oka virus vaccine. He was treated 
with oral acyclovir for 10 days. The OHS recommended further inves-
tigations and immune system evaluation in primary care settings. 
At 14 weeks after exposure, the patient presented again with symp-
toms of blurred vision. Ophthalmologic examination showed bilateral 
retinal necrosis. The fundus examination of both eyes showed the pro-
gressive retinal opacification and outer retinal necrosis. The intraocular 
pressures in both eyes were within the normal range of 16 - 18 mm Hg. 
Intravitreal sample for polymerase chain reaction (PCR) was positive 
for VZV with the same vaccine strain that was detected previously from 
the rash lesion.
Furthermore, VZV was found in the cerebrospinal fluid as well. The 
immunologic evaluation identified the Human Immunodeficiency 
Virus (HIV) with CD4 counts of 98/ml and a viral load of 266,000 
RNA copies/ml. The polymerase chain reaction (PCR) results for cyto-
megalovirus, herpes simplex, and Toxoplasma gondii were negative.
Therapy and Course. The patient was treated with intravitreal 
injections of gancyclovir and foscarnet. He also had received systemic 
treatment with intravenous acyclovir and foscarnet. Highly active anti-
retroviral therapy (HAART) was started based on laboratory findings 
of positive human immunodeficiency virus (HIV) test and CD4 count. 
After the start of HAART therapy and treatment, his visual acuity 
improved within three weeks. This case represented the health damage 
of the healthcare worker beyond the customary level of vaccination side 
effects and response, so it was subjected to a notification to the public 
health authorities.
DISCUSSION
Varicella-zoster infection can rise as a result of natural exposure 
to the wild-type virus, or through the vaccination that contains a 
live attenuated virus.1 This virus remains dormant in the dorsal root 
ganglia and can become reactivated in the later stage of life. Herpes 
zoster infection, also known as shingles, typically manifests as a 
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not cross the midline. However, disseminated infection can spread 
randomly across multiple dermatomes and have the potential to 
involve many internal body organs, such as lungs, liver, and central 
nervous system. Immunocompromised people are at a higher risk of 
developing a disseminated infection.8
Given the history of disseminated body rash and bilateral retinal 
necrosis, it is suggested that our patient had disseminated zoster due 
to the reactivation of the herpes zoster virus as a result of a live attenu-
ated vaccine. Moreover, the Oka strain analysis test confirmed the cause 
of generalized body rash and ocular symptoms. The patient met the 
diagnostic criteria for acute retinal necrosis. According to the American 
Uveitis Society, acute retinal necrosis is defined as greater than 1 foci of 
retinal necrosis along with other criteria, such as retinal arterial involve-
ment with occlusive vasculopathy, the progression of symptoms in the 
absence of active antiviral therapy, and finally a prominent inflamma-
tory reaction in anterior and vitreous chambers.9 Immunocompetent 
patients also may develop this, but immunocompromised individuals 
are more prone to severe disease. Moreover, more cases of acute retinal 
necrosis due to herpes simplex 2 virus have been observed in young 
people. In contrast, cases due to herpes simplex 1 or herpes zoster occur 
in the elderly.10
Even though many hundreds of thousands of people get vaccinated, 
complications of the vaccine as a result of virus replication rarely have 
been highlighted and reported.11 A clinical trial study involving more 
than 60,000 individuals reported a possible but unconfirmed case of 
Oka strain rash development within six weeks of immunization.11,12 
Moreover, a case of Oka strain herpes zoster also has been reported 
after shingles vaccine administration, but there was no retinal involve-
ment.13 Heath et al.14 reported a case of acute retinal necrosis caused by 
a zoster vaccine in an older patient with a confirmed Oka strain virus 
of the vaccine. There are two other cases of acute retinal necrosis after 
herpes zoster vaccination reported in the elderly, explaining the pos-
sible reactivation or infection by the Oka vaccine strain.15 However, 
to our knowledge, there was no case reported with a combination of 
clinical presentation of generalized body rash and acute bilateral retinal 
necrosis due to the Oka HZ vaccine virus strain.
Intravenous acyclovir has been regarded as a standard treatment for 
acute retinal necrosis. However, current guidelines recommended using 
oral valaciclovir or valganciclovir to treat acute retinal necrosis due to 
herpes simplex/zoster and cytomegalovirus, respectively.16 For those 
patients with valaciclovir resistance or with severe disease involving the 
optic nerve, intravitreal injection of foscarnet is recommended twice or 
thrice weekly. Oral corticosteroids are affected by patients with severe 
inflammation or sight-threatening disease with optic nerve involve-
ment.16
In this case report, the patient was immunocompromised due to HIV 
and exhibited varicella-zoster infection seven weeks after the vacci-
nation. His immune status put him at risk of disseminated varicella 
infection and acute retinal necrosis as it is one of the contraindications 
to the live attenuated vaccine.17 Additionally, despite the standard intra-
venous antiviral therapy for disseminated viral infection, the patient 
developed acute retinal necrosis several weeks after vaccination.
        POST-EXPOSURE HERPES ZOSTER VACCINATION
           continued.
CONCLUSIONS
In summary, a case of disseminated varicella infection and acute 
retinal necrosis was reported following varicella-zoster vaccination as 
a post-exposure protocol. This case highlighted that immunocompro-
mised persons are at high risk for disseminated rash and disseminated 
VZV disease following vaccination. Immune deficiency should be sought 
in atypical vaccine reaction, even in the setting of healthcare worker 
exposure investigation.
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